Pneumococcal Conjugate Vaccine (PCV)
Sponsors
Sanofi Pasteur Inc.
Conditions
Pneumococcal ImmunizationPneumococcal immunisation
Phase 3
A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2-arm study to
investigate the safety and immunogenicity of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers
RecruitingCTIS2023-507600-32-00
Start: 2025-05-22Target: 1080Updated: 2025-12-03
A Phase 3, randomized, modified double-blind, active-controlled, parallel-group study to investigate the safety and immunogenicity of catch-up vaccination regimens of a 21-valent pneumococcal
conjugate vaccine in healthy infants, toddlers, children, and adolescents
Active, not recruitingCTIS2024-512271-13-00
Start: 2025-05-08Target: 710Updated: 2025-12-18